Barclays Lifts CAG Price Target to $17 as Four Analysts Revise Conagra Outlooks

Barclays analyst Andrew Lazar maintained an Overweight rating on Conagra Brands, Inc. (NYSE: CAG) on Friday, July 17, raising his price target to $17 from $16. The revision was one of four analyst target updates on the packaged food company within two days, reflecting a fresh look at the stock following Conagra's fiscal fourth-quarter results reported on July 15.

What Changed

• Barclays (July 17): Andrew Lazar maintained Overweight, raised price target to $17 from $16.
• JP Morgan (July 16): Thomas Palmer maintained Neutral, raised price target to $15 from $14.
• UBS (July 16): Bryan Adams maintained Neutral, raised price target to $14 from $13.
• RBC Capital (July 16): Nik Modi maintained Sector Perform, lowered price target to $14 from $16.

Why It Matters

The cluster of revisions followed Conagra's July 15 earnings release, which market reports indicate included flat organic sales and forward guidance signaling continued pressure on volumes and margins in fiscal year 2027. Barclays stands as the lone Overweight voice among these four firms, with its $17 target representing the highest of the group and a premium of roughly 19% to Friday's closing price of $14.28.

RBC Capital's decision to cut its target to $14 from $16 contrasts with the upward moves from JP Morgan and UBS, illustrating a divided Street. The $3 spread between the lowest revised target ($14, from both UBS and RBC) and Barclays' $17 captures the range of views on how quickly Conagra can stabilize its top line and protect margins. All four firms maintained rather than changed their core ratings, meaning no upgrades or downgrades accompanied the target shifts.

Wall Street View

With four analysts active on the name this week, the prevailing stance leans cautious: three of the four firms hold neutral-equivalent ratings (Neutral or Sector Perform), while Barclays is the lone constructive voice at Overweight. The broader analyst community had shifted toward more cautious positioning entering this week, with the consensus as of July 1 showing 14 Hold ratings, 8 Sell ratings, and only 1 Buy out of 25 tracked recommendations, compared to 16 Hold and 1 Buy a month prior with no Sell ratings recorded.

Investor Takeaway

The divergence between Barclays' $17 target and RBC's $14 target highlights genuine uncertainty about Conagra's near-term earnings trajectory, particularly given the fiscal 2027 guidance that market reports characterize as signaling further volume and margin pressure. Shares fell -1.31% on Friday, July 17, while the S&P 500 declined -0.99%. For investors, the key variable to monitor is whether the company's cost-reduction efforts can offset volume softness as the new fiscal year progresses.